Urokinase plasminogen activator receptor and/or matrix metalloproteinase-9 inhibition induces apoptosis signaling through lipid rafts in glioblastoma xenograft cells. 2010

Chandramu Chetty, and Sajani S Lakka, and Praveen Bhoopathi, and Christopher S Gondi, and Krishna Kumar Veeravalli, and Daniel Fassett, and Jeffrey D Klopfenstein, and Dzung H Dinh, and Meena Gujrati, and Jasti S Rao
Department of Cancer Biology and Pharmacology, University of Illinois College of Medicine at Peoria, Peoria, Illinois 61605, USA.

Small interfering RNA (siRNA)-mediated transcriptional knockdown of urokinase plasminogen activator receptor (uPAR) and matrix metalloproteinase-9 (MMP-9), alone or in combination, inhibits uPAR and/or MMP-9 expression and induces apoptosis in the human glioblastoma xenograft cell lines 4910 and 5310. siRNA against uPAR (pU-Si), MMP-9 (pM-Si), or both (pUM-Si) induced apoptosis and was associated with the cleavage of caspase-8, caspase-3, and poly(ADP-ribose) polymerase. Furthermore, protein levels of the Fas receptor (APO-1/CD-95) were increased following transcriptional inactivation of uPAR and/or MMP-9. In addition, Fas siRNA against the Fas death receptor blocked apoptosis induced by pU-Si, pM-Si, or pUM-Si, thereby indicating the role for Fas signaling in pU-Si-, pM-Si-, or pUM-Si-mediated apoptotic cell death of human glioma xenograft cells. Thus, transcriptional inactivation of uPAR and/or MMP-9 enhanced localization of Fas death receptor, Fas-associated death domain-containing protein, and procaspase-8 into lipid rafts. Additionally, disruption of lipid rafts with methyl β cyclodextrin prevented Fas clustering and pU-Si-, pM-Si-, or pUM-Si-induced apoptosis, which is indicative of coclustering of Fas death receptor into lipid rafts in the glioblastoma xenograft cell lines 4910 and 5310. These data indicate the crucial role of the clusters of apoptotic signaling molecule-enriched rafts in programmed cell death, acting as concentrators of death receptors and downstream signaling molecules, and as the linchpin from which a potent death signal is launched in uPAR- and/or MMP-9-downregulated cells.

UI MeSH Term Description Entries
D008819 Mice, Nude Mutant mice homozygous for the recessive gene "nude" which fail to develop a thymus. They are useful in tumor studies and studies on immune responses. Athymic Mice,Mice, Athymic,Nude Mice,Mouse, Athymic,Mouse, Nude,Athymic Mouse,Nude Mouse
D001932 Brain Neoplasms Neoplasms of the intracranial components of the central nervous system, including the cerebral hemispheres, basal ganglia, hypothalamus, thalamus, brain stem, and cerebellum. Brain neoplasms are subdivided into primary (originating from brain tissue) and secondary (i.e., metastatic) forms. Primary neoplasms are subdivided into benign and malignant forms. In general, brain tumors may also be classified by age of onset, histologic type, or presenting location in the brain. Brain Cancer,Brain Metastases,Brain Tumors,Cancer of Brain,Malignant Primary Brain Tumors,Neoplasms, Intracranial,Benign Neoplasms, Brain,Brain Neoplasm, Primary,Brain Neoplasms, Benign,Brain Neoplasms, Malignant,Brain Neoplasms, Malignant, Primary,Brain Neoplasms, Primary Malignant,Brain Tumor, Primary,Brain Tumor, Recurrent,Cancer of the Brain,Intracranial Neoplasms,Malignant Neoplasms, Brain,Malignant Primary Brain Neoplasms,Neoplasms, Brain,Neoplasms, Brain, Benign,Neoplasms, Brain, Malignant,Neoplasms, Brain, Primary,Primary Brain Neoplasms,Primary Malignant Brain Neoplasms,Primary Malignant Brain Tumors,Benign Brain Neoplasm,Benign Brain Neoplasms,Benign Neoplasm, Brain,Brain Benign Neoplasm,Brain Benign Neoplasms,Brain Cancers,Brain Malignant Neoplasm,Brain Malignant Neoplasms,Brain Metastase,Brain Neoplasm,Brain Neoplasm, Benign,Brain Neoplasm, Malignant,Brain Neoplasms, Primary,Brain Tumor,Brain Tumors, Recurrent,Cancer, Brain,Intracranial Neoplasm,Malignant Brain Neoplasm,Malignant Brain Neoplasms,Malignant Neoplasm, Brain,Neoplasm, Brain,Neoplasm, Intracranial,Primary Brain Neoplasm,Primary Brain Tumor,Primary Brain Tumors,Recurrent Brain Tumor,Recurrent Brain Tumors,Tumor, Brain
D005909 Glioblastoma A malignant form of astrocytoma histologically characterized by pleomorphism of cells, nuclear atypia, microhemorrhage, and necrosis. They may arise in any region of the central nervous system, with a predilection for the cerebral hemispheres, basal ganglia, and commissural pathways. Clinical presentation most frequently occurs in the fifth or sixth decade of life with focal neurologic signs or seizures. Astrocytoma, Grade IV,Giant Cell Glioblastoma,Glioblastoma Multiforme,Astrocytomas, Grade IV,Giant Cell Glioblastomas,Glioblastoma, Giant Cell,Glioblastomas,Glioblastomas, Giant Cell,Grade IV Astrocytoma,Grade IV Astrocytomas
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000818 Animals Unicellular or multicellular, heterotrophic organisms, that have sensation and the power of voluntary movement. Under the older five kingdom paradigm, Animalia was one of the kingdoms. Under the modern three domain model, Animalia represents one of the many groups in the domain EUKARYOTA. Animal,Metazoa,Animalia
D014162 Transfection The uptake of naked or purified DNA by CELLS, usually meaning the process as it occurs in eukaryotic cells. It is analogous to bacterial transformation (TRANSFORMATION, BACTERIAL) and both are routinely employed in GENE TRANSFER TECHNIQUES. Transfections
D014183 Transplantation, Heterologous Transplantation between animals of different species. Xenotransplantation,Heterograft Transplantation,Heterografting,Heterologous Transplantation,Xenograft Transplantation,Xenografting,Transplantation, Heterograft,Transplantation, Xenograft
D015398 Signal Transduction The intracellular transfer of information (biological activation/inhibition) through a signal pathway. In each signal transduction system, an activation/inhibition signal from a biologically active molecule (hormone, neurotransmitter) is mediated via the coupling of a receptor/enzyme to a second messenger system or to an ion channel. Signal transduction plays an important role in activating cellular functions, cell differentiation, and cell proliferation. Examples of signal transduction systems are the GAMMA-AMINOBUTYRIC ACID-postsynaptic receptor-calcium ion channel system, the receptor-mediated T-cell activation pathway, and the receptor-mediated activation of phospholipases. Those coupled to membrane depolarization or intracellular release of calcium include the receptor-mediated activation of cytotoxic functions in granulocytes and the synaptic potentiation of protein kinase activation. Some signal transduction pathways may be part of larger signal transduction pathways; for example, protein kinase activation is part of the platelet activation signal pathway. Cell Signaling,Receptor-Mediated Signal Transduction,Signal Pathways,Receptor Mediated Signal Transduction,Signal Transduction Pathways,Signal Transduction Systems,Pathway, Signal,Pathway, Signal Transduction,Pathways, Signal,Pathways, Signal Transduction,Receptor-Mediated Signal Transductions,Signal Pathway,Signal Transduction Pathway,Signal Transduction System,Signal Transduction, Receptor-Mediated,Signal Transductions,Signal Transductions, Receptor-Mediated,System, Signal Transduction,Systems, Signal Transduction,Transduction, Signal,Transductions, Signal
D015533 Transcriptional Activation Processes that stimulate the GENETIC TRANSCRIPTION of a gene or set of genes. Gene Activation,Genetic Induction,Transactivation,Induction, Genetic,Trans-Activation, Genetic,Transcription Activation,Activation, Gene,Activation, Transcription,Activation, Transcriptional,Genetic Trans-Activation,Trans Activation, Genetic
D015536 Down-Regulation A negative regulatory effect on physiological processes at the molecular, cellular, or systemic level. At the molecular level, the major regulatory sites include membrane receptors, genes (GENE EXPRESSION REGULATION), mRNAs (RNA, MESSENGER), and proteins. Receptor Down-Regulation,Down-Regulation (Physiology),Downregulation,Down Regulation,Down-Regulation, Receptor

Related Publications

Chandramu Chetty, and Sajani S Lakka, and Praveen Bhoopathi, and Christopher S Gondi, and Krishna Kumar Veeravalli, and Daniel Fassett, and Jeffrey D Klopfenstein, and Dzung H Dinh, and Meena Gujrati, and Jasti S Rao
July 2010, Neurochemical research,
Chandramu Chetty, and Sajani S Lakka, and Praveen Bhoopathi, and Christopher S Gondi, and Krishna Kumar Veeravalli, and Daniel Fassett, and Jeffrey D Klopfenstein, and Dzung H Dinh, and Meena Gujrati, and Jasti S Rao
May 2003, Annals of vascular surgery,
Chandramu Chetty, and Sajani S Lakka, and Praveen Bhoopathi, and Christopher S Gondi, and Krishna Kumar Veeravalli, and Daniel Fassett, and Jeffrey D Klopfenstein, and Dzung H Dinh, and Meena Gujrati, and Jasti S Rao
January 2008, Molecular and cellular neurosciences,
Chandramu Chetty, and Sajani S Lakka, and Praveen Bhoopathi, and Christopher S Gondi, and Krishna Kumar Veeravalli, and Daniel Fassett, and Jeffrey D Klopfenstein, and Dzung H Dinh, and Meena Gujrati, and Jasti S Rao
December 2013, BMC cancer,
Chandramu Chetty, and Sajani S Lakka, and Praveen Bhoopathi, and Christopher S Gondi, and Krishna Kumar Veeravalli, and Daniel Fassett, and Jeffrey D Klopfenstein, and Dzung H Dinh, and Meena Gujrati, and Jasti S Rao
April 2007, Cell death and differentiation,
Chandramu Chetty, and Sajani S Lakka, and Praveen Bhoopathi, and Christopher S Gondi, and Krishna Kumar Veeravalli, and Daniel Fassett, and Jeffrey D Klopfenstein, and Dzung H Dinh, and Meena Gujrati, and Jasti S Rao
May 2003, Cancer research,
Chandramu Chetty, and Sajani S Lakka, and Praveen Bhoopathi, and Christopher S Gondi, and Krishna Kumar Veeravalli, and Daniel Fassett, and Jeffrey D Klopfenstein, and Dzung H Dinh, and Meena Gujrati, and Jasti S Rao
October 2010, Molecular and cellular biochemistry,
Chandramu Chetty, and Sajani S Lakka, and Praveen Bhoopathi, and Christopher S Gondi, and Krishna Kumar Veeravalli, and Daniel Fassett, and Jeffrey D Klopfenstein, and Dzung H Dinh, and Meena Gujrati, and Jasti S Rao
January 2006, Clinical & experimental metastasis,
Chandramu Chetty, and Sajani S Lakka, and Praveen Bhoopathi, and Christopher S Gondi, and Krishna Kumar Veeravalli, and Daniel Fassett, and Jeffrey D Klopfenstein, and Dzung H Dinh, and Meena Gujrati, and Jasti S Rao
January 2009, Clinical cancer research : an official journal of the American Association for Cancer Research,
Chandramu Chetty, and Sajani S Lakka, and Praveen Bhoopathi, and Christopher S Gondi, and Krishna Kumar Veeravalli, and Daniel Fassett, and Jeffrey D Klopfenstein, and Dzung H Dinh, and Meena Gujrati, and Jasti S Rao
June 2000, British journal of haematology,
Copied contents to your clipboard!